Gilead Closes Ouro Acquisition; Lakefront Gets $500M to Build Inflammation Pipeline
Gilead Sciences completed its acquisition of Ouro Medicines, repositioning Lakefront Biotherapeutics NV with at least $500 million in deployable cash and the Ouro portfolio as its core R&D foundation. The deal reflects sector-wide pressure from approaching patent cliffs, including JAKAFI's 2028 expiry, driving consolidation across biotech. Nanobiotix's CONVERGE trial posted a 57.1% complete response rate in Stage 3 NSCLC against a standard-of-care benchmark below 5%, validating the pipeline qual
Salvado•